Phibro's Sales Soar 27% on Strategic Zoetis Acquisition

TL;DR

**PAHC's aggressive acquisition strategy is paying off, making it a strong buy as it consolidates its position in the animal health market.**

AI Summary

Phibro Animal Health Corporation (PAHC) reported a robust fiscal year ended June 30, 2025, with total net sales surging by 27% to $1.296 billion from $1.018 billion in 2024. This significant growth was primarily driven by the Animal Health segment, which saw net sales increase by 36% to $963 million, largely due to the acquisition of Zoetis's medicated feed additive portfolio, contributing $208.2 million. Net income also experienced substantial growth, with Adjusted EBITDA climbing 65% to $184 million from $111 million in 2024. The company's strategic outlook includes continued investment in the companion animal sector, though its business remains concentrated in livestock. Key risks include potential FDA withdrawal of approval for Mecadox (carbadox), restrictions on antibacterial use, and geopolitical instability impacting operations in Israel and Brazil. The company completed the Zoetis acquisition for approximately $297.5 million, funded by term loan borrowings, expanding its product lines to over 37 and adding six manufacturing sites.

Why It Matters

Phibro's substantial 27% revenue growth and 65% Adjusted EBITDA increase, largely fueled by the Zoetis acquisition, signals strong market expansion and operational leverage for investors. This strategic move enhances PAHC's competitive position against larger players in the animal health sector by diversifying its product portfolio and manufacturing footprint across 80 countries. For employees, the acquisition of six new manufacturing sites suggests potential for job growth and expanded operational roles. Customers benefit from a broader range of animal health solutions, while the broader market sees increased consolidation and competition in the global animal health industry.

Risk Assessment

Risk Level: medium — The risk level is medium due to significant reliance on antibacterials, which face increasing regulatory scrutiny, including potential FDA withdrawal of Mecadox (carbadox) approval. Additionally, the company's dependence on Israeli and Brazilian operations exposes it to geopolitical instability, as highlighted by the armed conflicts between Israel and Hamas, and Russia and Ukraine, which could disrupt supply chains and demand.

Analyst Insight

Investors should consider PAHC's strong growth driven by the Zoetis acquisition as a positive indicator, but closely monitor regulatory developments regarding antibacterial products and geopolitical risks in key operating regions. The company's expanded product portfolio and manufacturing capabilities suggest long-term potential, warranting a hold or buy for those comfortable with the inherent industry and geographic risks.

Financial Highlights

revenue

$1.296B

revenue Growth

+27%

Revenue Breakdown

Key Numbers

• $1.296B — Total Net Sales (Increased 27% from $1.018 billion in 2024)
• $963M — Animal Health Segment Net Sales (Increased 36% from $706 million in 2024)
• $208.2M — Contribution from Zoetis Acquisition (Net sales contribution for the year ended June 30, 2025)
• $184M — Adjusted EBITDA (Increased 65% from $111 million in 2024)
• $297.5M — Zoetis Acquisition Purchase Price (Funded by term loan borrowings)
• 27% — Total Net Sales Growth (Year-over-year increase from 2024 to 2025)
• 65% — Adjusted EBITDA Growth (Year-over-year increase from 2024 to 2025)
• 80 — Countries of Operation (Number of countries where acquired Zoetis products are sold)
• 6 — Manufacturing Sites Acquired (Four in the U.S., one in Italy, one in China)
• $422,641,765 — Market Value of Non-Affiliate Class A and B Common Stock (As of December 31, 2024)

Key Players & Entities

• Phibro Animal Health Corporation (company) — registrant
• Zoetis Inc. (company) — seller in acquisition
• FDA (regulator) — Food and Drug Administration
• Mecadox (company) — product facing potential FDA withdrawal
• Nasdaq Stock Market (company) — exchange for Class A common stock
• Israel (regulator) — country of operation
• Hamas (regulator) — involved in armed conflict
• Russia (regulator) — involved in armed conflict
• Ukraine (regulator) — involved in armed conflict
• Delaware (regulator) — state of incorporation

FAQ

Risk Factors

• FDA Withdrawal of Mecadox Approval [high — regulatory]: The potential withdrawal of FDA approval for Mecadox (carbadox) is a significant risk, as a material portion of sales and gross profits are generated by antibacterials and related products. This could lead to a substantial decline in revenue.
• Restrictions on Antibacterial Use [high — regulatory]: Increasing global restrictions on the use of antibacterials in food-producing animals, including compliance with FDA Guidance 273, pose a risk. These limitations can directly impact sales of key products.
• Geopolitical Instability [medium — operational]: Operations in Israel and Brazil are subject to risks from geopolitical instability, including armed conflicts. This can disrupt manufacturing, supply chains, and sales in these key regions.
• Animal Disease Outbreaks [medium — market]: Outbreaks of animal diseases can significantly reduce demand for Phibro's products or impact the availability of raw materials, leading to decreased sales and operational challenges.
• Perceived Health Effects [medium — market]: Adverse perceptions linking the consumption of food derived from animals treated with Phibro's products to human health issues could cause a decline in sales.
• Competition [medium — market]: The company faces competition from numerous large and small companies, some of which possess greater financial, R&D, and production resources, potentially impacting market share and pricing.
• Pandemics and Infectious Diseases [medium — operational]: The negative effects of pandemics or outbreaks of infectious diseases on business, financial results, manufacturing, and supply chains, as well as on customers and markets, remain a risk.
• Climate Change [low — operational]: Climate change could materially adversely impact Phibro's operations and those of its customers, affecting resource availability and agricultural output.

Industry Context

Phibro operates in the global animal health and mineral nutrition market, serving livestock producers and veterinarians. The industry is characterized by consolidation among large commercial farms and increasing demand for solutions that enhance animal health, well-being, and food safety. Key trends include a growing focus on companion animals and ongoing regulatory scrutiny of antibacterial use in food-producing animals.

Regulatory Implications

Phibro faces significant regulatory risks, particularly concerning the potential FDA withdrawal of approval for its Mecadox product and increasing global restrictions on antibacterial use in food-producing animals, such as FDA Guidance 273. Compliance with these regulations is critical for maintaining product sales and market access.

What Investors Should Do

1. Monitor regulatory developments regarding antibacterials.
2. Assess the integration and performance of the Zoetis acquisition.
3. Evaluate diversification efforts into companion animals.
4. Consider geopolitical risks in Israel and Brazil.

Key Dates

• 2025-06-30: Fiscal Year End — Reported total net sales of $1.296 billion, a 27% increase from the prior year, with Animal Health segment sales reaching $963 million.
• 2025-06-30: Fiscal Year End — Adjusted EBITDA grew 65% to $184 million, indicating improved profitability and operational efficiency.
• 2024-04-01: Zoetis Acquisition Completed — Acquisition of Zoetis's medicated feed additive portfolio for approximately $297.5 million, funded by term loan borrowings, significantly boosting Animal Health segment sales.
• 2024-12-31: Market Value Measurement — Market value of non-affiliate Class A and B common stock was $422,641,765.

Glossary

Medicated Feed Additive

Products containing approved drugs that are added to animal feed to prevent, treat, or control diseases in livestock. (The acquisition of Zoetis's medicated feed additive portfolio was a primary driver of Phibro's significant sales growth in the Animal Health segment for FY2025.)

Adjusted EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization, adjusted for certain non-recurring or non-operational items. It's a measure of a company's operating performance. (Phibro's Adjusted EBITDA increased by 65% to $184 million, highlighting strong operational performance and profitability improvements.)

FDA Guidance 273

A guidance issued by the U.S. Food and Drug Administration related to the judicious use of medically important antimicrobials in food-producing animals. (Compliance with and the increasing prevalence of such guidance globally represent a regulatory risk that could restrict the use of Phibro's antibacterial products.)

Anticoccidials

Drugs or substances used to prevent or treat coccidiosis, a parasitic disease common in poultry and livestock. (These are a key product category within Phibro's Animal Health segment, contributing to disease prevention and animal performance.)

Mineral Nutrition

Products designed to supplement animal diets with essential minerals to support health, growth, and well-being. (This is a core business segment for Phibro, complementing its animal health offerings.)

Class A and Class B Common Stock

Different classes of common stock that may have different voting rights or other privileges. Class A is traded on Nasdaq, while Class B is not. (Indicates the company's capital structure and how its shares are traded, with market value provided for non-affiliate shares.)

Year-Over-Year Comparison

Phibro Animal Health Corporation demonstrated substantial year-over-year growth in fiscal year 2025. Total net sales surged by 27% to $1.296 billion, largely propelled by a 36% increase in the Animal Health segment, significantly boosted by the Zoetis acquisition. Adjusted EBITDA saw an impressive 65% rise to $184 million, indicating strong operational leverage and improved profitability. New risks related to geopolitical instability in Israel and Brazil were highlighted, alongside ongoing concerns about regulatory actions on antibacterials.

Key Financial Figures

• $297.5 million — on at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of ca
• $286.5 m — price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquire
• $407.6 million — uct portfolio acquired, which generated $407.6 million in revenue in 2023, is comprised of mor
• $208.2 million — 025, this product portfolio contributed $208.2 million to our overall net sales. Also included

Filing Documents

• pahc-20250630x10k.htm (10-K) — 4739KB
• pahc-20250630xex10d20.htm (EX-10.20) — 43KB
• pahc-20250630xex10d21.htm (EX-10.21) — 57KB
• pahc-20250630xex10d22.htm (EX-10.22) — 56KB
• pahc-20250630xex21d1.htm (EX-21.1) — 38KB
• pahc-20250630xex23d1.htm (EX-23.1) — 2KB
• pahc-20250630xex31d1.htm (EX-31.1) — 11KB
• pahc-20250630xex31d2.htm (EX-31.2) — 11KB
• pahc-20250630xex32d1.htm (EX-32.1) — 7KB
• pahc-20250630xex32d2.htm (EX-32.2) — 7KB
• pahc-20250630x10k009.jpg (GRAPHIC) — 89KB
• pahc-20250630xex10d20g001.jpg (GRAPHIC) — 228KB
• pahc-20250630xex10d20g002.jpg (GRAPHIC) — 216KB
• pahc-20250630xex10d20g003.jpg (GRAPHIC) — 182KB
• pahc-20250630xex10d20g004.jpg (GRAPHIC) — 36KB
• pahc-20250630xex10d20g005.jpg (GRAPHIC) — 275KB
• pahc-20250630xex10d20g006.jpg (GRAPHIC) — 254KB
• pahc-20250630xex10d20g007.jpg (GRAPHIC) — 202KB
• pahc-20250630xex10d20g008.jpg (GRAPHIC) — 90KB
• pahc-20250630xex10d20g009.jpg (GRAPHIC) — 110KB
• pahc-20250630xex10d20g010.jpg (GRAPHIC) — 133KB
• pahc-20250630xex10d20g011.jpg (GRAPHIC) — 41KB
• pahc-20250630xex10d20g012.jpg (GRAPHIC) — 182KB
• pahc-20250630xex10d20g013.jpg (GRAPHIC) — 174KB
• pahc-20250630xex10d20g014.jpg (GRAPHIC) — 171KB
• 0001558370-25-011776.txt ( ) — 22652KB
• pahc-20250630.xsd (EX-101.SCH) — 118KB
• pahc-20250630_cal.xml (EX-101.CAL) — 167KB
• pahc-20250630_def.xml (EX-101.DEF) — 442KB
• pahc-20250630_lab.xml (EX-101.LAB) — 859KB
• pahc-20250630_pre.xml (EX-101.PRE) — 873KB
• pahc-20250630x10k_htm.xml (XML) — 3769KB

Forward-Looking Statements and Risk Factors Summary

Forward-Looking Statements and Risk Factors Summary 3 Market Ranking and Other Industry Data 5 Trademarks, Service Marks and Trade Names 5 PART I Item 1.

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 29 Item 1B. Unresolved Staff Comments 57 Item 1C. Cybersecurity 57 Item 2.

Properties

Properties 59 Item 3.

Legal Proceedings

Legal Proceedings 60 Item 4. Mine Safety Disclosures 60 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 61 Item 6. (Reserved) 62 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 85 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 86 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 132 Item 9A.

Controls and Procedures

Controls and Procedures 132 Item 9B. Other Information 132 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 132 PART III Item 10. Directors, Executive Officers and Corporate Governance 133 Item 11.

Executive Compensation

Executive Compensation 133 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 133 Item 13. Certain Relationships and Related Transactions, and Director Independence 133 Item 14. Principal Accountant Fees and Services 133 PART IV Item 15. Exhibits and Financial Statement Schedules 134 Item 16. Form 10-K Summary 138

SIGNATURES

SIGNATURES 139 2 Table of Contents

Forward-Looking Statements and Risk Factors Summary

Forward-Looking Statements and Risk Factors Summary This Annual Report on Form 10-K contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim," "anticipate," "believe," "estimate," "expect," "forecast," "outlook," "potential," "project," "projection," "plan," "intend," "seek," "may," "could," "would," "will," "should," "can," "can have," "likely," the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include: outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials; perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products; restrictions on the use of antibacterials in food-producing animals may become more prevalent, including limitation

Business

Item 1. Business Overview Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through animal feed manufacturers, wholesalers, distributors and veterinarians. Our products include: Animal health products such as antibacterials, anticoccidials, nutritional specialty products, and vaccines and vaccine adjuvants that help improve the animal's health and therefore improve performance, food safety and animal welfare. Our Animal Health segment also includes antibacterials and other processing aids used in the ethanol fermentation industry. Mineral nutrition products that fortify the animal's diet and help maintain optimal health. We have focused our efforts in regions where the majority of livestock production is consolidated in large commercial farms. We believe we are well positioned to grow our sales with our established network of sales, marketing and distribution professionals in markets in North America, Latin America, Asia Pacific, Europe, Africa and the Middle East. We are investing resources to further develop products for the companion animal sector. Our business is currently concentrated in the livestock sector. In addition to animal health and mineral nutrition pr

View Full Filing

View this 10-K filing on SEC EDGAR